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ABSTRACT
Introduction: The estimation of utility values
for the economic evaluation of therapies for wet
age-related macular degeneration (AMD) is a
particular challenge. Previous economic models
in wet AMD have been criticized for failing to
capture the bilateral nature of wet AMD by
modelling visual acuity (VA) and utility values
associated with the better-seeing eye only.
Methods: Here we present a de novo regression
analysis using generalized estimating equations
(GEE) applied to a previous dataset of time tra-
de-off (TTO)-derived utility values from a
sample of the UK population that wore contact
lenses to simulate visual deterioration in wet
AMD. This analysis allows utility values to be
estimated as a function of VA in both the bet-
ter-seeing eye (BSE) and worse-seeing eye (WSE).
Results: VAs in both the BSE and WSE were
found to be statistically significant (p\0.05)
when regressed separately. When included
without an interaction term, only the coeffi-
cient for VA in the BSE was significant
(p = 0.04), but when an interaction term
between VA in the BSE and WSE was included,
only the constant term (mean TTO utility value)
was significant, potentially a result of the
collinearity between the VA of the two eyes. The
lack of both formal model fit statistics from the
GEE approach and theoretical knowledge to
support the superiority of one model over
another make it difficult to select the best
model.
Conclusion: Limitations of this analysis arise
from the potential influence of collinearity
between the VA of both eyes, and the use of
contact lenses to reflect VA states to obtain the
original dataset. Whilst further research is
required to elicit more accurate utility values for
wet AMD, this novel regression analysis pro-
vides a possible source of utility values to allow
future economic models to capture the quality
of life impact of changes in VA in both eyes.
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INTRODUCTION
Wet age-related macular degeneration (wet
AMD) is a chronic ophthalmic condition asso-
ciated with severe visual impairment in older
adults [1]. Left untreated, wet AMD leads to a
progressive loss of visual acuity (VA; the ability
of the eye to resolve fine detail) which affects
the capacity to which patients can continue
with routine activities such as driving, reading,
and recognizing faces, and can have a substan-
tial impact on health-related quality of life
(HRQoL) [2, 3].
In the United Kingdom (UK), measurement of
HRQoL is an important aspect of the clinical
benefit of novel therapies, where cost-utility
analysis is the preferred method of health tech-
nology assessment (HTA) recommended by the
National Institute of Health and Care Excellence
(NICE) to assess the relative value of novel inter-
ventions to the UKNational Health Service (NHS)
[4]. In cost-utility analysis, the health benefits of a
new treatment are expressed in quality-adjusted
life years (QALYs),where eachyearof life lived ina
particular health state is weighted with a utility
value (from 0 to 1) based on a valuation of pref-
erence for that health state [5, 6].
NICEguidance states that themeasurementof
changes in HRQoL should be reported directly
from patients (e.g., collected directly from a
clinical trial) [4]. The utility values associated
with these changes should, however, be derived
from a valuation of public preferences from a
representative sample of the UK general popula-
tion using a generic preference-based method
(i.e., one applicable to a wide range of diseases,
patients, and interventions, to allow for deci-
sion-making across the whole of the NHS) [4].
NICE’s preferred generic preference-based
method of utility value elicitation is the EuroQol
Health Questionnaire 5 Dimensions (EQ-5D)—a
patient-reported questionnaire with five
domains covering mobility, self-care, usual
activities, pain/discomfort, and anxiety/
depression—the scores of which can be con-
verted to a validated set of utility values thathave
beenvaluedbymembers of theUKgeneral public
using the time trade-off (TTO) methodology [7].
A recent systematic literature review identi-
fied eight publications reporting UK-derived
utility values for wet AMD [2]. Only two
UK-based utility studies have been published in
wet AMD that use the NICE-preferred EQ-5D,
demonstrating the paucity of data for this
measure [8, 9]. Furthermore, neither of these
studies found that the utility values elicited via
this method reflected the change in visual
impairment of the patients in the studies [8, 9].
This lack of relationship may lie with the
descriptive nature of generic tools such as the
EQ-5D, and the fact that the domains covered
do not explicitly capture the impact of vision
loss on activities of daily living, particularly for
a disease such as wet AMD which is neither
painful nor life-threatening.
Alternatively, several studies have elicited
utility values via direct valuation from patients
with AMD, using the TTO, standard gamble
(SG), and visual analogue scale (VAS) valuation
techniques [8–11]. The utilization of patients to
directly value the utility of a certain health state
lends itself to the possibility of underestimation
of utility values due to the concept known as
adaptation, when patients with a chronic con-
dition adapt to their situation and therefore rate
their health state less severely than would a
member of the general population unaffected
by the condition [12]. An additional concern
with the valuation of hypothetical health states
by members of the general public, however, is
the ability of participants to accurately imagine
these particular health states. In the study by
Czoski-Murray et al., members of the general
UK population were given contact lenses with a
central opacity to simulate different states of
vision loss, and utility values were elicited using
the TTO methodology. When comparing the
TTO-derived utilities with those derived via the
Health Utilities Index-3 (HUI-3), EQ-5D, Short
Form-6 Dimensions (SF-6D), and TTO by
Espallargues et al. [8], Czoski-Murray et al.
found a stronger significant correlation between
VA in the BSE and the TTO-elicited utility values
derived through the use of different contact
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lenses, than those derived by Espallargues et al.
for the HUI-3 and the EQ-5D, as well as those
elicited directly via TTO from a population of
wet AMD patients (i.e., without contact lenses)
[8]. Whilst the opacity of the contact lenses has
been criticized for simplifying the full effects of
wet AMD on VA [13, 14], the study by
Czoski-Murray et al. offers an interesting
attempt to address the challenges associated
with utility value elicitation in wet AMD and
forms the basis of the de novo regression anal-
ysis presented in this publication.
The economic models submitted to NICE for
the technology appraisals of ranibizumab and
pegaptanib in wet AMD were ‘‘one-eye’’ Markov
state-transition models that assumed only the
better-seeing eye (BSE) was treated, with utility
values associatedwithVAof theBSEonly [15].Use
of this approach assumes that any improvement
in VA in the worse-seeing eye (WSE) results in no
utility gain. In clinical practice, however, it is
typically thefirstpresentingeye that is treatedand
approximately 70% of these eyes are in fact the
WSE [16, 17]. Nevertheless, the vast majority of
published wet AMD utility studies have been
performed on the basis of the VA of the BSE, for
which there is most evidence of a correlation
between VA and utility. By not including any
effects on utility from the VA of the WSE within
the economic evaluation of new therapies in wet
AMD, the clinical benefit of the intervention
under appraisal may be being underestimated.
Conversely, in a casewhere utility values basedon
theVAof the BSE are used as a proxy for treatment
of theWSE, the clinical benefit of anew treatment
may be being overestimated. In the NICE tech-
nology appraisal of aflibercept for wet AMD, the
health economic model submitted by the manu-
facturer was again criticized for being a ‘‘one-eye’’
model that assumed the untreated eye had no
visual impairment at the start of themodel. It was
therefore representative of a WSE model, but the
utility values used had been derived using EQ-5D
within the pivotal clinical trial and therefore
included a wider set of patients that was appro-
priate for a WSE model [18].
Whilst the utility values from the paper by
Czoski-Murray et al. were considered appropri-
ate in the technology appraisal for ranibizumab
in wet AMD, they are based on VA of the BSE
only and do not account for VA of the WSE [19].
Wet AMD is a bilateral disease yet there is a
paucity of evidence on the extent to which
changes in VA of the WSE contribute to overall
patient HRQoL. In an attempt to address this
limitation and the uncertainties raised by NICE
regarding the estimation of utility values as a
function of VA in both eyes, we present here a
de novo regression analysis based on the dataset
from Czoski-Murray et al. that explores the
estimation of utility as a function of VA in both
the BSE and the WSE [19]. This analysis was
briefly introduced in a recent paper by Claxton
et al. [14], and is presented in full in this
publication.
METHODS
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
Description of Dataset
In the studybyCzoski-Murray et al., a total of 108
subjects from the general UK population were
recruited to wear three sets of custom-made
contact lenses with differing central opacities
[19]. The three sets of lenses were used to repro-
duce three states of differing VA representing
differing severities of wet AMD, measured
according to the logarithm of the minimal angle
of resolution (LogMAR), with LogMAR scores of
0.6 (Snellen equivalent 20/80) (reading limit),
1.0 (20/200) (legal blindness), and 1.4 (20/500)
(the state to which patients with untreated AMD
deteriorate), respectively. The TTO technique
was then used to assess participant valuation of
their own health state both before wearing the
lenses and during each of the three health state
simulations [19].
The sampled population was considered
younger (mean 32 years, 7 years younger than
average UK population), more likely to be
employed (66%), and more likely to be educated
to degree level (28%) than the general public
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(Table 1) [19]. These background characteristics
were explained by the difficulties in recruit-
ment; 66 of the 108 subjects had to be recruited
by word of mouth from colleagues and study
participants after only 42 of a random sample of
2000 people attended to complete prior inter-
views [19]. Of the 108 subjects, four did not
continue testing with all three contact lenses
because of complications in the fitting process
[19].
The original analysis by Czoski-Murray et al.
adjusted the TTO-derived utility values for
(i) the effect of the lenses, by removing all
baseline observations so that differences in
utility values between health states were due to
the change in VA rather than the effect of the
lens itself; and (ii) the order of the lenses, by
adjusting the utility values for each of the pos-
sible lens orders using ordinary least squares
(OLS) regression (Table 2) [19].
Methodology
In the Czoski-Murray et al. analysis, the relation-
ship between the TTO-derived utility values and
VA, with and without adjusting for age, was
explored in the BSE only using OLS. In this
extended re-analysis of the Czoski-Murray et al.
dataset, LogMAR VA in the WSE was also inclu-
ded, thereby allowing the results to be used
within health economic models that incorporate
the effect of VA in both eyes on utility.
Five regression models were used to estimate
the effect on utility of VA: (1) in the BSE alone;
(2) in the WSE alone; (3) in both eyes inde-
pendently; (4) in both eyes with an interaction
between VA in the BSE andWSE; and (5) in both
eyes with an interaction term and an additional
blindness threshold. Models 4 and 5 were
included to account for an effect on utility from
the VA in both eyes, thereby allowing for a
non-linear relationship between the influence
of the VA on each eye. In both the analysis by
Czoski-Murray et al. and early testing for this
re-analysis, age was found to be a non-signifi-
cant predictor of utility and hence was excluded
as a covariate from all five models. All statistical
modelling, including model fitting, inference,
predictions, and validation, was carried out in
Stata V14.1.
The five models are described below; b0 is
the constant term and represents the mean
Table 1 Baseline characteristics of the dataset from
Czoski-Murray et al. (n = 108) Adapted from
Czoski-Murray et al. [19]
Characteristic Summary statistics
Mean age (SD) 32.1 (12.5)
Employed (%) 66%
Degree-level education (%) 28%
Long-standing illness (%) 23%
Mean TTO utility (SD) 0.960 (0.109)
BSE distant LogMAR (SD) - 0.0494 (0.123)
WSE distant LogMAR (SD) 0.0481 (0.192)
BSE better-seeing eye, LogMAR logarithm of the minimal
angle of resolution, SD standard deviation, WSE
worse-seeing eye
Table 2 Mean-adjusted TTO-derived utility values from Czoski-Murray et al. [19]
LogMAR VA
in the BSE
Lens 1 Lens 2 Lens 3 Overall
n Utility value n Utility value n Utility value n Utility value
B 0.3 18 0.778 23 0.649 0 – 41 0.706
0.31–0.60 40 0.731 40 0.649 9 0.603 89 0.681
0.61–1.30 46 0.653 41 0.486 38 0.366 125 0.511
C 1.31 0 – 0 – 56 0.314 56 0.314
Total 104 0.705 104 0.585 103 0.358 311 0.550
BSE better-seeing eye, LogMAR logarithm of the minimal angle of resolution, TTO time trade-off, VA visual acuity
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TTO utility value. Changes in VA in the BSE
and WSE are denoted by the variables VABSE
and VAWSE, respectively, which may be
incorporated using either LogMAR or Early
Treatment Diabetic Retinopathy Study
(ETDRS) letters data. In this re-analysis, the
models were fitted with LogMAR VA data from
the Czoski-Murray et al. study.
Model 1: BSE Model
Assumes utility is affected by VA in the BSE
only. b1 represents the mean change in TTO
utility associated with a 1-unit change in VA of
the BSE.
TTO ¼ b0 þ b1VABSE:
Model 2: WSE Model
Assumes utility is affected by VA in the WSE
only. b2 represents the mean change in TTO
utility associated with a 1-unit change in VA of
the WSE.
TTO ¼ b0 þ b2VAWSE:
Model 3: BSE and WSE Model
Assumes utility is affected by VA in the BSE and
WSE, independently. b1 represents the mean
change in TTO utility associated with a 1-unit
change in VA in the BSE, if there is no change in
VA in the WSE, and the reverse for b2.
TTO ¼ b0 þ b1VABSE þ b2VAWSE:
Model 4: BSE, WSE, and BSE–WSE Interaction
Model
Assumes utility is affected by VA in the BSE and
WSE independently, in addition to a combina-
tion of VA in the BSE and WSE. b1 and b2 have
the same clinical interpretation as in model 3. If
VAs of both the BSE and WSE change by 1 unit
in the same direction, this additional mean
change in TTO utility is represented by b3.
TTO ¼ b0 þ b1VABSE þ b2VAWSE þ b3VAWSE
 VABSE:
Model 5: BSE, WSE, and BSE–WSE Interaction
Model Plus ‘‘Blind’’ Variable
b1, b2, and b3 have the same clinical interpre-
tation as in model 4. b4BLIND is an indicator
variable that takes a value of 1 if VA falls below
35 ETDRS letters (equivalent to LogMAR[1.0)
in both eyes (or zero otherwise), in relation to
the psychological impact of a patient becoming
legally blind.
TTO ¼ b0 þ b1VABSE þ b2VAWSE þ b3VAWSE
 VABSE þ b4BLIND:
As subjects contributed a maximum of three
TTO values to the dataset from each of the three
differing contact lens pairs, the data were
therefore not fully independent and an OLS
regression approach, which assumes data
independence, would likely underestimate the
standard errors of the coefficients, leading to
the invalidation of further statistical tests. As
such, generalized estimating equations (GEEs)
were used to account for relationships between
observations from the same individual and
produce robust standard errors that better
reflected the dependence structure in the data.
GEEs no longer assume that the residual errors
in the regression model are normally distributed
and uncorrelated, but instead assume that the
residual errors are correlated and can be
estimated by a correlation matrix. The five
models were fitted using the following three
correlation structures:
• Exchangeable Assumes equal correlation
between all observations by the same subject
• Independent Assumes no correlation between
observations by the same subject, equivalent
to an OLS approach
• Unstructured Makes no assumptions about
the correlations between observations by the
same subject
The results from fitting all three correlation
structures to each of the five models were
compared. Since likelihood ratio tests are not
available for GEEs, comparison between models
concentrated on the root mean squared error
(RMSE).
RESULTS
In early testing, the relationship between the
TTO-derived utility values and VA in both the
BSE and WSE without interaction was explored
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using OLS. This suggested that the residuals
were negatively skewed (Fig. S1), which may
have been caused by a ‘‘ceiling’’ effect from
many patients reporting a utility value of 1
(perfect health), leading to poor predictive
quality at the extremes. Additionally, VAs in the
BSE and WSE were found to be highly corre-
lated, suggesting possible collinearity between
these variables (Fig. S2).
Although there was little difference in model
fit between the three correlation structures, the
exchangeable structure was deemed the most
clinically plausible because of the assumption
that there would be equal correlation between
subject observations in addition to the usual
variation between observations from different
subjects. Results from the exchangeable corre-
lation structure are presented in Table 3; results
from the independent and unstructured
correlation structures are presented in the sup-
plementary material (Tables S1 and S2).
Both VA in the BSE and VA in the WSE were
found to be highly significant when regressed
separately with the mean TTO-derived utility
values in model 1 and model 2, respectively
(both p\0.01) (Table 3). As might be expected,
the effect of VA in the BSE on utility was slightly
higher than that of VA in the WSE (associated
with a smaller p value). When VA in the BSE and
VA in the WSE were included independently of
each other in model 3, both variables had
smaller coefficients and larger standard errors
compared with those estimated in models 1 and
2, respectively. In model 3, only VA in the BSE
was found to be significant (p = 0.04), but when
an interaction term between VA in the BSE and
WSE was included in model 4, only the con-
stant term (mean TTO utility value) was found
Table 3 Estimates of coefficients from GEEs, dependent variable is TTO utility (exchangeable errors)
Model 1: BSE
model
GEE
(exchangeable)
Model 2: WSE
model
GEE
(exchangeable)
Model 3: BSE and
WSE model
GEE
(exchangeable)
Model 4: WSE
and BSE–WSE
interaction model
GEE
(exchangeable)
Model 5: WSE
and BSE–WSE
interaction model
plus blind
dummy
GEE
(exchangeable)
b Robust
SE
b Robust
SE
b Robust
SE
b Robust
SE
b Robust
SE
BSE (b1) - 0.324
*** 0.029 – – - 0.182* 0.087 - 0.039 0.153 - 0.042 0.158
WSE (b2) – – - 0.320
*** 0.034 - 0.151 0.098 - 0.079 0.109 - 0.085 0.109
Interaction
(b3)
– – – – – – - 0.113 0.090 - 0.105 0.116
Blindness
(b4)
– – – – – – – – - 0.007 0.079
Constant
(b0)
0.817*** 0.029 0.864*** 0.035 0.848*** 0.038 0.769*** 0.073 0.771*** 0.073
Obs 311 308 308 308 308
RMSE 0.280 0.283 0.280 0.281 0.281
BSE better-seeing eye, GEE generalized estimating equations, Obs observations, RMSE root mean squared error, SE standard
error, WSE worse-seeing eye
*p\0.05; **p\0.01; ***p\0.001
 Standard error adjusted for clustering
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to be significant. Furthermore, the coefficient
for VA in the WSE in model 4 was larger than
the coefficient for VA in the BSE, and had a
smaller standard error. The same conclusions
were found with the inclusion of the BLIND
indicator variable in model 5 which was also
found to be a non-significant predictor of util-
ity. Interestingly, on the basis of RMSE, there
was little difference between all five models.
These results may be indicative of the pres-
ence of collinearity between VA in the BSE and
VA in the WSE, which may be causing impre-
cision in the estimation of their coefficients
when they are both included in the model. This
is most noticeable with the inclusion of the
interaction term in model 4 and model 5, where
VA in the WSE was shown to have a larger
independent effect than VA in the BSE. This
would be considered clinically implausible and
also led to no terms, including VA in either the
BSE or WSE, being statistically significant. Sim-
ilar conclusions were found when using the
independent and unstructured correlation
matrices (presented in supplementary material).
Similarly, the lack of statistical significance of
the BLIND variable may be due to the full psy-
chological impact of becoming blind not being
adequately captured by the subjects enrolled in
the study as they were members of general UK
population.
Figure 1 provides predicted utility estimates
from each of the five regression models using
the exchangeable correlation structure. Fig-
ures 1d and e indicate that as VA in the BSE
decreases, the models with the BSE and WSE
interaction term provide slightly higher utility
estimates than the model without this interac-
tion (Fig. 1b). There is also very little difference
in prediction with the inclusion of the blind-
ness threshold from model 4 to 5 (Fig. 1d, e),
further indicating the non-significance of the
BLIND variable.
DISCUSSION
The estimation of utility values for the eco-
nomic evaluation of therapies for wet AMD is
Fig. 1 Predicted utility estimates from models 1 to 5
(exchangeable structure). a Model 1: BSE model;
b model 2: WSE model; c model 3: BSE and WSE model
(independent); d model 4: BSE, WSE, and BSE–WSE
interaction model; e model 5: BSE, WSE, and BSE WSE
interaction model plus blind. BSE better-seeing eye,
LogMAR logarithm of the minimal angle of resolution,
WSE worse-seeing eye
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associated with considerable challenges and
uncertainty. In particular, the health economic
models submitted for the NICE technology
appraisals of ranibizumab, pegaptanib and
aflibercept in wet AMD received criticism for
failing to capture the bilateral nature of the
disease [15, 18]. These health economic models
only accounted for the treatment of one eye,
assumed to be the BSE, with utility values linked
to VA in the BSE only. Overall patient HRQoL
derives from the VA in both eyes and, in clinical
practice, the first eye to be treated is more often
the WSE [20]. Modelling of the BSE only could
lead to a recommendation for treatment in the
BSE only, which may result in one eye known to
be affected by AMD deteriorating without
treatment, which could be associated with
considerable patient anxiety and depression
[15]. These typical ‘‘one-eye’’ cohort models do
not enable changes in VA in both eyes to be
modelled over time [15]; hence, modelling of
the VA in both the BSE and the WSE, along with
any resulting change in HRQoL from treatment
of the WSE, is desirable.
Current approaches to the elicitation and
application of utility values may, therefore, not
be accurately capturing the potential QALY gains
associated with treatment, which in turn may
impact HTA decision-making. The regression
analysis presented here advances the derivation
of utility values for wet AMD in this regard. Five
different regression models that explored utility
as a function of VA in the BSE andWSE alone and
together were evaluated using a GEE approach.
Whilst utility was found to be statistically sig-
nificantly related toVA in the BSE andWSE alone
when evaluated independently (in models 1 and
2), the regression models that captured the
impact of the change in VA in both eyes together
(model 4 and model 5) may potentially be con-
sidered superior, as they allow for a non-linear
relationship between VA and utility that is
dependent on the VA of both eyes. However, the
lack of formal model fit statistics available from
theGEE approach and the shortage of theoretical
knowledge to support the superiority of one
model over another make it difficult to select the
best model.
The relationship between VA and utility is a
complex one, and whilst there are several
aspects that can be considered, they are not
easily explored. This analysis is limited by the
degree of collinearity observed between the
variables for the VA in the BSE and WSE; this is
unsurprising given that two identical contact
lenses were applied to each participant in each
simulation state. This makes the effects of VA in
the WSE and BSE difficult to disentangle and
may have led to inflated standard errors and
invalid conclusions regarding the individual
coefficients for VA in the BSE and WSE in
models 3–5. Although collinearity appears to be
heavily influencing the coefficient estimates,
the overall effect on model prediction is
unclear. Earlier testing identified possible issues
related to model prediction attributed to the
‘‘ceiling’’ effect which the GEE approach also
fails to address. Furthermore, there is also the
possible issue that when the VA of two eyes
becomes quite similar, the BSE may not neces-
sarily be the dominant eye. As the VA of the
WSE improves, for example with treatment, this
could potentially lead to a loss of utility, an
aspect that is not factored into this analysis.
Furthermore, this analysis evaluated only five
selected models; hence, several other paramet-
ric models were not explored.
In addition, a limitation of this analysis
arises from the nature of the original study
conducted by Czoski-Murray et al. [19]. The
population used in the dataset was much
younger and more likely to be employed and
educated to degree level than the general pop-
ulation. In addition, the use of contact lenses in
the study by Czoski-Murray et al. [19] has been
criticized for failing to capture the full effects of
wet AMD on vision loss [13]. Indeed, a recent
study by Butt et al. found that contact lenses are
not a good simulation for the symptoms expe-
rienced, as people experience only a dimming
of light and blurring of the image, rather than
the true scotoma that would be expected with
wet AMD [13]. Moreover, issues that emerged
during the lens fitting process, with some
patients unable to tolerate the use of the lenses,
could have had an impact on the utility values
reported [13]. As such, further work on a more
representative set of the general population and
using alternative methods such as virtual reality
to aid the accurate simulation of vision loss
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associated with wet AMD would be of value.
Additionally, the Czoski-Murray dataset does
not meet the NICE reference case as it used TTO
rather than EQ-5D to derive utilities. However,
given the reported insensitivity of the EQ-5D
and other generic measures to changes in VA,
and that NICE has previously accepted the TTO
values from Czoski-Murray et al., this analysis is
still useful for future models in the UK setting.
Furthermore, the Czoski-Murray et al. dataset
was also used to inform the utility values for the
health economic model constructed for the
draft NICE clinical guidelines on the manage-
ment of AMD, further highlighting the
acknowledgement of this dataset by NICE [21].
The utility values derived using the different
exchangeable regression models described here
have been used in a recent economic evalua-
tion of ranibizumab versus aflibercept for wet
AMD [14]. This paper by Claxton et al.
demonstrates the practical use of this regres-
sion analysis and its importance to future
economic evaluations for this disease [14]. The
results of this cost-effectiveness analysis
demonstrated that the scenario that incorpo-
rated utility values based on the BSE eye only
(model 1) provided a substantially higher esti-
mate of total QALY gains compared with the
scenario based on the WSE only (model 2),
providing evidence to support the use of a
‘‘two-eye’’ regression model (i.e., models 3–5).
In this cost-effectiveness analysis, regression
models 3–5 included the VA of both eyes and
provided QALY estimates in between those for
model 1 and model 2 [14]. Utilization of a
‘‘two-eye’’ health economic model with a
regression model based on the VA of both eyes
to estimate utility values would enable the
capture of visual improvement regardless of
which eye is treated, and could therefore be
considered most preferable. The modelling of
two eyes, however, requires more sophisticated
economic modelling techniques such as simu-
lation modelling; hence, advances in both the
derivation of utility values and the way in
which economic models are built are needed to
adequately capture changes in VA and HRQoL
in the future economic evaluation of novel
therapies in ophthalmology.
CONCLUSION
Further research is required to elicit more
accurate utility values for wet AMD involving
the VA of both eyes, in addition to advances in
the technical economic modelling of oph-
thalmic conditions. Until such utility values are
available, the regression analysis presented here
represents a possible source of data that could
be considered in the economic evaluation of
future therapies for wet AMD in the UK, which
will allow economic models to capture the
quality of life impact of changes in VA in both
eyes.
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